https://www.fool.com/investing/2020/07/30/johnson-johnsons-coronavirus-vaccine-candidate-eff.aspx
Johnson & Johnson (NYSE:JNJ) By Keith Speights
Lix shirkadood ayaa hadda qiimeynaya natoojin la soo saaray oo ku aadan tallaalka COVID-19.
J&J waxay ka mid ahaayeen kuwa ugu horreeyay ee sameeya ilaha dadaalka weyn ee lagula dagaallamayo COVID-19. Waxay aasaasay iskaashi lala yeesho dawladda Mareykanka goor hore si loo soo saaro tallaalka coronavirus ee sheeko cusub. Waa shirkadda ugu weyn ee daryeelka caafimaadka adduunka, oo leh ilo ballaaran. Hadana weli Johnson iyo Johnson waxay si wanaagsan uga dambeeyaan xafiiltan badan, yar iyo weynba.
Ha dhimin rajooyinka J&J, in kastoo, bixinta rajada weyn ee daryeelka caafimaad ee tallaalka COVID-19 uu lahaan karo dal,da lool, hadana waxa uu noqon kara guul ugu weyn oo la gaaray
Johnson & Johnson waxay ku dhawaaqeen daabacaada natiijooyinka ka soo baxday daraasad la taaban karo oo ku saabsan murashaxiinta hogaamisa tallaalka, Ad26.COV2-S, Luulyo 30. Ka dib oo dhan, dhowr ka mid ah kuwa J & J ee tartanka ku jira si ay u horumariyaan tallaallada COVID-19 ayaa durba ku dhawaaqay natiijooyinka daraasadaha caafimaad ee heerka koowaad ee aadanaha.
Shirkadda ayaa sheegtay in tallaalkeeda tijaabada ah ay keentay jawaab celin adag oo dhanka difaaca ah oo ku saabsan aasaaska bini’aadamka. Gaar ahaan, tallaalka Ad26.COV2-S waxay dhalisay soo-saarisyo heerar sare oo ka-hortagga unugyada difaaca jirka, kuwaas oo leh awoodda looga hortago infekshanka cudurka coronavirus. J&J waxay xustay in murashaxdeeda tallaalku ay siisay “difaac dhammaystiran ama ku dhow dhow sanbabka laga helo fayraska” xayawaanka daraasadda saxda ah.
Waxaas oo dhami waxay ahaayeen war weyn. Laakiin waxa runtii keenay natiijooyinkaan durugsan waxay ahayd in jawaabcelintii difaaca ee cajiibka ahayd lagu helay kaliya hal qadar oo ah Ad26.COV2-S. Murashaxiinta kale ee tallaalka COVID-19 ee ka sii sii gudbaya baaritaanka caafimaad waxay u baahan yihiin laba qaadasho.
Waxaa jira dhowr sababood oo muhiim ah sababta tallaalka “hal-iyo-kaliya” looga doorbido tallaallada u baahan qiyaaso badan. Marka hore, tallaal hal-tallaal ah ayaa ka raqiisan. Marka labaad, dadku waxay u badan tahay inay helaan hal qaddar tallaal ah halkii ay ka heli lahaayeen labada qaadasho tallaal ee u baahan laba.
Wali waa xilli hore, in kastoo. J&J waxay qiimeyneysaa labada-hal iyo laba-qiyaasood oo ah Ad26.COV2-S wejigiisa 1 / 2a daraasadaha caafimaad. Shirkaddu waxay sidoo kale qorsheyneysaa inay ku darto labada daawo qaadasho ee daraasadeed wejigeeda 3aad ee daraasadda. Waxaa jira suurtagal in tijaabadu u horseedi karto J&J inay raacdo habka laba-qiyaasta ah. Si kastaba ha noqotee, haddii tallaalka hal-ku-tallaalku u shaqeynayo sidoo kale aadanaha uu ka hooseeyo kuwii hore ee aan ahayn bina-aadamnimada, Johnson iyo Johnson ayaa si fudud uga soo kaban kara laggard una noqon kara hogaamiyaha tallaalka COVID-19.
Johnson iyo Johnson ayaa si la yaab leh uga sii hadhay tartankii lagu horumarinayay tallaalka COVID-19. In kasta oo ay shirkaddu rajaynayso in ay biloowdo daraasad dabayaaqadeed oo Ad26.COV2-S ah bisha Sebtember, haddana wali si fiican bay uga dambaysaa dhowr dawo oo kale. Waxa kale oo laga yaabaa inaad la yaabto in J&J uu ku guuleystay kaliya oggolaanshaha sharci ee hal tallaal – weligiis. Ansixintaasina waxay timid bishii la soo dhaafay, iyadoo oggolaanshaha yurub ee tallaalka shirkadda ee cudurka Ebola.
Laakiin J&J wuxuu umuuqdaa inuu ciyaaraya ciyaarta dhaadheer sifiican oo ay u socoto horumarkiisa talaalka COVID-19. Waqti badan ayey qaadatay si loo aqoonsado murashax ay dhici karto in lagu maareeyo hal daawo oo keliya. Shirkaddu sidoo kale waxay ku dalacdaa wax kayar talaalkiisa marka loo eego kuwa ay xafiiltamaan ee ugu sarreeya. Toddobaadkii la soo dhaafay, J&J waxay la gashay dowladda Mareykanka inay bixiso 100 milyan oo qiyaasood oo ah Ad26.COV2-S qiyaastii $ 1 bilyan. Isbarbar dhig ahaan, Pfizer iyo BioNTech waxay Mareykanka siinayaan 100 milyan oo qadar ah $ 1.95 bilyan.
Qiimo hoose oo leh qaddar yar oo loo baahan yahay ayaa umuuqan kara istiraatiijiyad caqli gal ah. Miyaanu J&J ka samayn karin lacag aad u badan iibinta lacag laba-tallaal ah oo qiimihiisu ka badan yahay kuwa kula tartamaya? Hubaal. Saamiyada daryeelka caafimaadka ayaa laga yaabaa inay sii ahaato sanad ka badan sidii hore haddii ay qaadatay qaabkan.
Si kastaba ha noqotee, tallaal hal-tallaal ah ayaa aad u soo jiidanaya dawladaha adduunka oo dhan. Iyo J&J ayay u badan tahay inay ku iibiyaan qiimo iyada oo aafadu weli socoto. Ka dib markay masiibadaas dhammaatay, ka filna shirkadda inay sicirkeeda kor u qaaddo.
Xusuusnow sheekada Aesop ee ku saabsan ijaaridda iyo bakaylaha? Waxay umuuqataa Johnson iyo Johnson inay noqon karaan tortoise tartanka loogu jiro soo saarida tallaalka COVID-19. Xanuunku waa laga yaabaa inuu ku guuleysto orodka adduunka dhabta ah – sida ay ku jirtey sheekooyinka.
https://www.fool.com/investing/2020/07/30/johnson-johnsons-coronavirus-vaccine-candidate-eff.aspx